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Abstract: Donors not meeting standard criteria, such as those with
bacteremia, are now being used in response to the increasing need
for organs for transplantation. Recommended strategies to prevent
the occurrence of donor-derived bacteremia include the use of
directed antibiotic prophylaxis. However, this approach does not
eliminate the risk of infection transmission. Similarly, the
management of organ recipients from donors with infective
endocarditis (IE) remains uncharacterized. We report 2 cases of
donor-derived bacterial infections in liver transplant recipients
despite pathogen-specific antibiotic prophylaxis. In both instances,
the donors had documented IE treated with appropriate
antimicrobial therapy and clearance of bacteremia. Recipients had
very distinctive clinical outcomes likely related to pathogen
virulence and the extent of donor infection. Persistent infection in
the transplanted liver should be suspected in organ recipients of a
liver from donors with IE, despite the absence of bacteremia at the
time of death and organ procurement. For eradication, recipients
may require prolonged pathogen-directed antimicrobial therapy,
such as is used for endovascular infections. Prompt recognition of
donors with IE, appropriate notification, and prolonged antibiotic
prophylaxis are key to reducing the risk of such donor-derived
infections.
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Organs from donors not meeting standard donor
criteria, such as donors with bacteremia or infective
endocarditis (IE), are now utilized in response to the
increasing need for organs for transplantation (1).
Recommended strategies to prevent the occurrence of
donor-derived bacteremia include the use of directed
antibiotic prophylaxis (2). However, this approach
does not eliminate the risk of infection transmission.
Similarly, the management of organ recipients from
donors with IE remains uncharacterized. Between
December 2012 and March 2013, 2 cases of donor-
derived bacterial infections in liver transplant (LT)
recipients were identified at Henry Ford Hospital, an
802-bed tertiary care center in Detroit. In both instances
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the donors had been appropriately treated for IE and
had clearance of bacteremia at the time of death.
Case reports
Case 1
A 59-year-old man, with congenital aortic stenosis
status post aortic valve replacement, and end-stage-
liver disease secondary to hepatitis C complicated with
hepatocellular carcinoma treated with chemoemboliza-
tion and radio frequency ablation, received an LT.
Immunosuppressive regimen included induction with
basiliximab and maintenance with tacrolimus, myco-
phenolate mofetil, and prednisone. Opportunistic infec-
tions prophylaxis included fluconazole, trimethoprim-
sulfamethoxazole, and valganciclovir as per protocol.
The donor was a 31-year-old woman with lupus
erythematous and end-stage renal disease on hemo-
dialysis performed through a PermCath, who devel-
oped fever during hemodialysis. Blood cultures the day
before and for 5 subsequent days following hospital
admission were positive for vancomycin- and ampicillin-
susceptible Enterococcus faecalis (VSE). Transthoracic
echocardiogram showed a mobile vegetation on the
posterior mitral valve leaflet (0.85 cm 9 0.5 cm) and
mild mitral valve regurgitation. The patient (donor) was
treated for IE with intravenous (IV) vancomycin and
subsequently with high-dose ampicillin (VSE demon-
strated high-level resistance to aminoglycoside). Clin-
ical course of the donor was further complicated by
poor venous access after removal of the PermCath. The
patient subsequently had a new PermCath placed after
clearance of bacteremia on hospital day 10. She then
developed acute deep vein thrombosis of the right
lower extremity requiring anticoagulation.
On day 17, the patient sustained a fall with blunt head
trauma. Computerized tomography (CT) scan of the
head showed a large hemorrhage in the right basal
ganglia with mid-line shift. The patient had progressive
neurologic status deterioration and subsequently
needed resuscitation for cardiac arrest with pulseless
electrical activity. After resuscitation, the patient
remained unresponsive with asymmetric pupils. The
patient was subsequently declared brain dead. Only the
liver was accepted for transplantation. Of note, blood
cultures from days 6, 10, and 17 of hospitalization, and
at time of organ procurement, were negative. The
donor did not undergo an autopsy.
The LT recipient received cefepime and metronida-
zole for surgical prophylaxis. On post-transplant day 1,
accessory left hepatic artery bleeding developed,
necessitating an exploratory laparotomy and ligation
of the artery. Because of postoperative fevers and
leukocytosis, cefepime and metronidazole were contin-
ued and vancomycin was added on postoperative day
(POD) 1. Blood cultures obtained on POD 1 were
negative. On POD 5, Infectious Diseases was consulted
because of persistence of fevers despite broad-spec-
trum antibiotic coverage. Given the known history of
Enterococcus species bacteremia in the donor, vanco-
mycin was switched to daptomcyin (8 mg/kg/day)
pending detailed information about the donor’s infec-
tion from Gift of Life (GOL). Within the next day, GOL
confirmed recent history of persistent bacteremia with
VSE sensitive to ampicillin, vancomycin, and daptomy-
cin, and high-level gentamicin synergy resistance.
Based on this information, IV ampicillin (1 g q 6 h)
was added. The patient remained febrile and on POD 9
developed hypotension.
A CT scan of the abdomen showed a large intra-
abdominal hematoma. A second laparotomy and evac-
uation of the hematoma was performed. Cultures of the
hematoma yielded E. faecalis. Ampicillin was discon-
tinued owing to development of a drug-related rash.
The patient completed an additional 3 weeks of therapy
with daptomycin. On work-up, no other site of infection
including IE was identified.
The patient remains well at 6 months of follow up.
The antibiograms (Table 1) and pulse field gel electro-
phoresis (PFGE) typing patterns (Fig. 1) of the VSE
isolated from the donor blood cultures and the recipient
hematoma cultures were identical.
Case 2
A 41-year-old man, with a model for end-stage-liver
disease (MELD) score of 40 secondary to primary
sclerosing cholangitis and ulcerative colitis, received an
LT. Immunosuppression included induction with anti-
thymocyte globulin followed by maintenance with
tacrolimus, mycophenolate mofetil, and prednisone.
At the time of LT the recipient was on IV daptomycin
(4 mg/kg/day) for the treatment of soft tissue infec-
tion. He had completed treatment for an episode of
Clostridium difficile-associated diarrhea (CDAD). Sur-
gical prophylaxis in the recipient included cefepime and
metronidazole, in addition to the daptomycin therapy
for cellulitis. Opportunistic infections prophylaxis
included fluconazole, trimethoprim-sulfamethoxazole,
and valganciclovir, as per protocol.
The donor was a 22-year-old man, an active IV drug
user who was found unresponsive in the street. He was
taken to the local Emergency Department, where he
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was found to have an elevated temperature of 105°F
and a large occipital bleed. Broad-spectrum antibiotics
(i.e., vancomycin and piperacillin-tazobactam) were
started immediately. Initial blood cultures were
reported positive for gram-positive cocci in clusters,
and the patient was continued on vancomycin and
piperacillin-tazobactam. A transthoracic echocardio-
gram showed a mobile mass on anterior mitral valve
leaflet with moderate-to-severe mitral regurgitation,
indicative of left-sided IE. His blood cultures were
confirmed positive for methicillin-resistant Staphylococ-
cus aureus (MRSA). Subsequent blood cultures were
negative, documenting clearance of bacteremia.
Despite aggressive supportive measures, he remained
unresponsive, and was declared brain dead. By the time
of organ procurement, the donor had received antimi-
crobial therapy active against MRSA and had remained
afebrile for more than 2 days. Blood cultures at the
time of procurement showed no growth. The liver, both
lungs, one kidney and pancreas, and the second kidney
were transplanted to 4 recipients. No evidence of intra-
abdominal infection was noted at the time of organ
procurement. Unfortunately, the donor did not undergo
an autopsy.
Intraoperative donor liver biopsy at the time of
transplant was culture negative, but blood cultures,
obtained from the recipient 3 h after the LT procedure,
yielded MRSA. Daptomycin dose was increased to
8 mg/kg/day on POD 1 after transplant surgery, once
the donor MRSA susceptibilities became available.
Repeat blood cultures obtained 5 days after LT were
negative. Work-up including ultrasound of the liver and
CT scans of the abdomen and pelvis were negative for
any deep-seated infection, and multiple repeat blood
cultures remained negative.
After documenting clearance of MRSA bloodstream
infection (BSI), and negative work-up for deep-seated
MRSA infection, a peripherally inserted central catheter
(PICC) line was placed for long-term IV antibiotic
treatment. The patient remained asymptomatic and
clinically stable, and was discharged to a rehabilitation
center where he completed 3 weeks of therapy with
high-dose daptomycin (8 mg/kg/day). The PICC line
was removed at the end of IV antibiotic treatment.
Seven weeks after discontinuation of daptomycin
(week 10 post LT), the patient was hospitalized with
fevers and chills, neutropenia, and elevated liver
transaminases. Blood cultures were obtained, and
empiric therapy with IV vancomycin, cefepime, and
metronidazole was initiated. Blood culture yielded
MRSA with a vancomycin minimum inhibitory concen-
tration (MIC) of 2 mcg/mL, and the antibiotic regimen
was de-escalated to IV vancomycin (goal trough 15–
20 mcg/mL).
CT chest scan revealed multiple bilateral pulmonary
nodular infiltrates and CT scans of the abdomen and
Antibiotic susceptibilities of the bacterial isolates
Antibiotic susceptibilities (MIC lg/mL)
Cases Pathogen AMP OXA VAN GEN DAP* Other
Case 1
Donor Enterococcus
faecalis
S (MIC <2) NA S (MIC = 1) R NA R
Recipient E. faecalis S (MIC <2) NA S (MIC = 1) R NA R
Case 2
Donor MRSA NA R S (MIC ≤2) S (MIC ≤0.5) NA Clindamycin
(MIC ≤0.5)
Recipient (First episode,
6 Dec 2012)
MRSA NA R (MIC >4) S (MIC = 1.5) S (MIC ≤0.5) S (MIC = 1) Clindamycin –
S (MIC ≤0.25)
Recipient (Second episode,
16 Feb 2013)
MRSA NA R (MIC >4) S (MIC = 2) S (MIC ≤0.5) S (MIC ≤0.25) Clindamycin –
S (MIC ≤0.25)
Recipient (Third episode,
5 May 2013)
MRSA (5/5/13) NA R (MIC >4) S (MIC = 1.5) S (MIC <0.5) S (MIC = 1) Linezolid –
S (MIC = 2)
*E-test was used for determining the MIC for daptomycin.
MIC, minimum inhibitory concentration; AMP, ampicillin; OXA, oxacillin; VAN, vancomycin; GEN, gentamicin; DAP, daptomycin; S, sensitive; NA,
not available; R, resistant; MRSA, methicillin-resistant Staphylococcus aureus.
Table 1
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pelvis showed splenic infarcts. Blood cultures became
negative within 24 h after therapy. A transthoracic
echocardiogram showed no evidence of IE. However,
given the concern for septic emboli in the lungs and
spleen complicating MRSA bacteremia, the patient
received 8 weeks of IV vancomycin therapy.
Two weeks after completion of vancomycin therapy
(week 20 post LT) the patient was hospitalized for
treatment of recurrent CDAD. During hospitalization,
the patient developed fevers and chills. Blood cultures
were positive for MRSA, and daptomycin (8 mg/kg/
day) was restarted. Repeat blood cultures were nega-
tive after 48 h of treatment. An echocardiogram
showed no features of IE. The patient completed
8 weeks of therapy with daptomycin.
The patient remained well 3 months after completion
of therapy. The MRSA blood culture isolates from the 3
episodes of bacteremia in the recipient had identical
PFGE patterns (Fig. 2); antibiotic susceptibilities of
each isolate are summarized in Table 1. During an
investigation carried out by the Centers for Disease
Control and Prevention, MRSA DNA extracted from
fixed donor heart valve tissue was matched to theMRSA
isolated from the first episode of bacteremia in the
recipient, confirming donor-derived transmission (3).
Of note, in addition to our liver recipient, the lung
recipient from this donor also developed post-transplant
donor-derived MRSA bacteremia, despite vancomycin
therapy initiated at the time of transplantation (3). The
recipients of the right kidney, and the left kidney and
pancreas did not develop MRSA bacteremia. Both these
patients received vancomycin prophylaxis for 5 days
after transplant surgery because of the donor MRSA
bacteremia.
Discussion
Donor-derived infections among solid organ transplant
recipients continue to occur despite the increasing
efforts focused on prevention and donor screening (1,
4). The utilization of organs from donors not meeting
standard donor criteria has been associated with
increased transmission of infections (5, 6).
Factors associatedwith increased riskof infection in the
donor include prolonged stay in the intensive care unit
(>3 days), whereas older age of the donor was associated
with higher rates of infection transmission (5).
Fig. 2. Pulse field gel electrophoresis patterns of Case 2. Lane 1:
Lambda DNA ladder; Lane 2: MRSA isolate from first episode of
bacteremia in recipient (6 Dec 2012); Lane 3: MRSA isolate from
second episode of bacteremia in recipient (15 Feb 2013); and Lane 4:
MRSA from third episode of bacteremia in recipient (5 May 2013).
Fig. 1. Pulse field gel electrophoresis patterns of Case 1. Lane 1:
Lambda DNA ladder; Lane 2: VSE isolate from recipient; Lane 3: VSE
isolate from donor.
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Previously, the presence of bacteremia and IE was
considered a contraindication for organ retrieval (7, 8).
More recent data suggest that organs from a donor
with bacteremia and IE can be safely used, provided the
donor received appropriate antimicrobial treatment for
at least 48 h and antibiotic therapy is continued in the
organ recipient (5, 9–13).
We present 2 cases of donor-derived bacterial infec-
tions in LT recipients despite pathogen-specific antibi-
otic coverage. In both instances, the donors had
documented left-sided IE treated with pathogen-specific
antimicrobial therapy and subsequent clearance of
bacteremia. Interestingly, each recipient had a very
distinctive clinical course. Our first patient (Case 1) had
a less complicated course, having received broad-
spectrum antibiotic treatment after LT because of
signs of infection and the history of donor enterococcal
IE. All blood cultures remained negative, probably
because of ongoing antimicrobial therapy. However,
intra-abdominal hematoma culture was positive for
VSE. The patient completed 3 weeks of antibiotics
and remains well at 9 months of follow up.
The second recipient (Case 2) had a more compli-
cated clinical course with surveillance blood culture,
performed immediately after transplant surgery, being
positive for MRSA (first episode), despite being on
daptomycin therapy for cellulitis at a dose of 4 mg/kg/
day, compared to the higher dose recommended for the
treatment of MRSA BSI (i.e., 6 mg/kg/day). Repeat
blood cultures remained negative after antimicrobial
therapy. The patient relapsed (second episode) with
MRSA bacteremia, 2 months after completing a 3-week
course of antibiotics. Despite completing an additional
8 weeks of directed antibiotic therapy, the patient had a
second relapse (the third episode) of MRSA bacteremia.
The first recurrence of MRSA bacteremia in this
patient may be the consequence of a shorter duration of
therapy, 3 weeks instead of the 4 weeks that current
guidelines recommend for the treatment of complicated
MRSA BSI (14). The second recurrence, after 8 weeks
of vancomycin therapy, may have been in part caused
by the higher but still susceptible vancomycin MIC
(2 mcg/mL) of the MRSA isolate. Suboptimal response
to vancomycin therapy has been reported in infections
caused by vancomycin-susceptible strains of MRSA
with MIC >1.5 mcg/mL, as well as a possible upward
“creep” in vancomycin MIC (15).
Solid organ transplant recipients at risk for donor-
derived bacteremia may require prolonged courses of
therapy with extremely active antimicrobial treatment,
to prevent transmission of infection from donors with
IE and to optimize outcomes. In the setting of MRSA IE
in the donor, combination therapy with beta-lactams or
cotrimoxazole may be an option to improve the
antibacterial activity of daptomycin for the prevention
and treatment of persistent or relapsing MRSA bacter-
emia (16–18).
The different clinical outcome of these 2 patients
could be explained by the extent of dissemination of
infection in the donor and the virulence of the pathogen
causing IE. Our first patient, with an intra-abdominal
VSE-infected hematoma, had a more benign course.
E. faecalis is considered a moderately virulent patho-
gen and enterococcal IE is rarely associated with
metastatic infection. These 2 factors, and the prompt
evacuation of the infected hematoma, most likely
explain the rapid resolution of the infection in this
case. In the second case, the donor had MRSA IE with
multiple septic emboli (including to the brain) (3).
Indeed, disseminated foci of infection in bacteremic
donors have been associated with a higher risk of
transmission (19). Moreover, highly virulent patho-
gens, such as MRSA, have been associated with post-
transplant endovascular infections including mycotic
aneurysms (20–23). Donor transmission of bacteremia
is reported to occur in up to 5.8% of LT recipients,
despite antibiotic prophylaxis. Previous observations
suggest that the risk of transmission is higher among
LT recipients compared to other organ recipients (5, 6).
Doucette et al. (6) have proposed that increased risk of
transmission in LT recipients may be multifactorial. It
may be attributed to (a) the greater likelihood of
infection in the liver, owing to the large mass of tissue
and rich vasculature, as well as bacterial retention in
the liver secondary to impaired phagocytosis and
killing, in the setting of brain death and organ
procurement; and (b) because of recipient-related
factors, such as a high MELD score, leukopenia,
immunosuppression, and poor antibiotic penetration
to the transplanted liver (6). In the antibiotic era, septic
emboli to the liver and mycotic aneurysms of the
hepatic artery are considered rare complications of left-
sided IE (24, 25). However, these could have been
possible factors for the multiple relapses of MRSA
infection in our second recipient.
Many questions remain unanswered about the man-
agement of recipients of organs from donors with IE,
including the optimal duration of antibiotic prophylaxis,
and requirement for and timing of surveillance blood
cultures (e.g., should all recipients be monitored, or
only those receiving organs from donors infected with
more virulent pathogens such as MRSA, Pseudomonas
aeruginosa, multidrug-resistant organisms). No stan-
dard recommendation is available about the duration of
antibiotic treatment for bacteremic recipients in this
setting. Based on published case series, most experts
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recommend at least 2 weeks of directed antimicrobial
therapy (5, 6, 9, 10) and longer treatment (2–4 weeks)
for S. aureus and P. aeruginosa infections (19).
To decrease the risk of transmission of infection from
liver donors with IE we suggest: (a) detailed review of
the clinical data of bacteremic donors to identify
possible cases of IE; (b) detailed documentation of
the pathogen causing bacteremia, antibiotic suscepti-
bilities, agent used, and duration of antibiotic therapy,
response to therapy, and clearance of bacteremia; (c)
prompt reporting of this information, and the likelihood
of IE, to the transplant teams; and (d) pathogen-
directed prolonged (3–4 weeks) antibiotic therapy for
any LT recipient of a liver from a donor with IE.
Our report illustrates that transmission of infection
from donors with IE may occur despite antibiotic
prophylaxis. Maximizing effective team communication
and detailed donor information are critical to guide the
management of these serious infections.
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